News & Updates
Search Research Content
Resource Finder at Kennedy Krieger Institute
A free resource that provides access to information and support for individuals and families living with developmental disabilities.
A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy.
|Title||A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy.|
|Publication Type||Journal Article|
|Year of Publication||2013|
|Authors||Zhang L, Yang J, Cai J, Song X, Deng J, Huang X, Chen D, Yang M, Wery J-P, Li S, Wu A, Li Z, Li Z, Liu Y, Chen Y, Li Q, Ji J|
A preclinical trial identified 4 of 20 (20%) gastric cancer (GC) patient-derived xenografts responded to cetuximab. Genome-wide profiling and additional investigations revealed that high EGFR mRNA expression and immunohistochemistry score (3+) are associated with tumor growth inhibition. Furthermore, EGFR amplification were observed in 2/4 (50%) responders with average copy number 5.8 and >15 respectively. Our data suggest that a GC subtype with EGFR amplification and overexpression benefit from cetuximab treatment.
|Alternate Journal||Sci Rep|